Next Article in Journal
The Out-of-Pocket Cost Burden of Cancer Care—A Systematic Literature Review
Previous Article in Journal
Implementing a 3As and ‘Opt-Out’ Tobacco Cessation Framework in an Outpatient Oncology Setting
Article

Circulating miR-618 Has Prognostic Significance in Patients with Metastatic Colon Cancer

1
Department of Biochemistry, Molecular Medicine and Nutrigenomics, Medical University of Varna, 9000 Varna, Bulgaria
2
Clinic of Medical Oncology, Military Medical Academy, 1000 Sofia, Bulgaria
3
Department of General and Clinical Pathology, Forensic Medicine and Deontology, Medical University of Varna, 9000 Varna, Bulgaria
4
Second Department of Internal Diseases, Medical University of Varna, 9000 Varna, Bulgaria
5
Department of Oncology, Medical University of Varna, 9000 Varna, Bulgaria
6
Clinic of Medical Oncology, Hospital Nadezhda, 1000 Sofia, Bulgaria
*
Author to whom correspondence should be addressed.
Received: 27 January 2021 / Revised: 28 February 2021 / Accepted: 11 March 2021 / Published: 15 March 2021
(This article belongs to the Section Gastrointestinal Oncology)
The present study evaluated the prognostic role of circulating miRNA-618 in patients with metastatic colon cancer (mCC) and whether miR-618 gene rs2682818 single nucleotide polymorphisms (SNP) are associated with colon cancer susceptibility and expression levels of mature miR-618. In total, 104 patients with mCC before starting the chemotherapy were investigated. The expression status of circulating miR-618 in mCC was evaluated by quantitative PCR. TaqMan PCR assay was used for rs2682818 SNP genotyping. miR-618 was overexpressed in serum of mCC patients. Patients with high and intermediate expression of miR-618 had a significantly longer mean overall survival (OS) of 21 months than patients with low expression—16 months. In addition, multivariate Cox regression analysis confirmed the association between high/intermediate levels of miRNA-618 and longer OS, HR = 0.51, 95% CI: 0.30–0.86, p = 0.012. miR-618 rs2682818 SNP significantly decreased the risk of colon cancer susceptibility in both heterozygous codominant (AC vs. CC, OR = 0.39, 95% CI: 0.17–0.88, p = 0.024) and overdominant (AC vs. CC + AA, OR = 0.37, 95% CI: 0.16–0.85, p = 0.018) genetic models. Our data suggest that circulating miRNA-618 could be useful as a prognostic biomarker in mCC. Patients harboring AC rs2682818 genotype have a decreased risk for colon cancer in comparison with patients with CC and AA genotypes. View Full-Text
Keywords: metastatic colon cancer; miR-618; rs2682818 metastatic colon cancer; miR-618; rs2682818
Show Figures

Figure 1

MDPI and ACS Style

Radanova, M.; Mihaylova, G.; Mihaylova, Z.; Ivanova, D.; Tasinov, O.; Nazifova-Tasinova, N.; Pavlov, P.; Mirchev, M.; Conev, N.; Donev, I. Circulating miR-618 Has Prognostic Significance in Patients with Metastatic Colon Cancer. Curr. Oncol. 2021, 28, 1204-1215. https://0-doi-org.brum.beds.ac.uk/10.3390/curroncol28020116

AMA Style

Radanova M, Mihaylova G, Mihaylova Z, Ivanova D, Tasinov O, Nazifova-Tasinova N, Pavlov P, Mirchev M, Conev N, Donev I. Circulating miR-618 Has Prognostic Significance in Patients with Metastatic Colon Cancer. Current Oncology. 2021; 28(2):1204-1215. https://0-doi-org.brum.beds.ac.uk/10.3390/curroncol28020116

Chicago/Turabian Style

Radanova, Maria, Galya Mihaylova, Zhasmina Mihaylova, Desislava Ivanova, Oskan Tasinov, Neshe Nazifova-Tasinova, Pavel Pavlov, Milko Mirchev, Nikolay Conev, and Ivan Donev. 2021. "Circulating miR-618 Has Prognostic Significance in Patients with Metastatic Colon Cancer" Current Oncology 28, no. 2: 1204-1215. https://0-doi-org.brum.beds.ac.uk/10.3390/curroncol28020116

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop